A to Z Drug Facts 2010
Author | : |
Publisher | : |
Total Pages | : 0 |
Release | : 2010 |
Genre | : Drugs |
ISBN | : 9781574392913 |
Download A to Z Drug Facts 2010 Book in PDF, ePub and Kindle
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download A To Z Drug Facts 2010 PDF full book. Access full book title A To Z Drug Facts 2010.
Author | : |
Publisher | : |
Total Pages | : 0 |
Release | : 2010 |
Genre | : Drugs |
ISBN | : 9781574392913 |
Author | : David S. Tatro |
Publisher | : Lippincott Williams & Wilkins |
Total Pages | : 1540 |
Release | : 2006 |
Genre | : Medical |
ISBN | : |
This compact, portable, alphabetically organized drug reference provides quick access to current, reliable information on more than 4,500 commonly prescribed medications. Each drug monograph is divided into pharmacological and patient care considerations, and includes action, indications, contraindications, route/dosage, interactions, lab test interferences, adverse reactions, precautions/warnings, administration/storage, assessment/interventions, and patient/family education. Icons and a second color are used to help readers quickly locate the information they are looking for. Coverage includes the newest FDA approvals, investigational and orphan drugs, and indications for labeled, unlabeled, and orphan uses. The included Drug Identifier CD-ROM enables readers to search and identify drugs by appearance.
Author | : |
Publisher | : |
Total Pages | : 1321 |
Release | : 2000 |
Genre | : Drugs |
ISBN | : 9781574390681 |
Author | : |
Publisher | : |
Total Pages | : 0 |
Release | : 2001 |
Genre | : |
ISBN | : |
Author | : Linda Skidmore-Roth |
Publisher | : |
Total Pages | : 1018 |
Release | : 1991 |
Genre | : Medical |
ISBN | : 9780801661976 |
Author | : National Academies of Sciences, Engineering, and Medicine |
Publisher | : National Academies Press |
Total Pages | : 483 |
Release | : 2017-09-28 |
Genre | : Medical |
ISBN | : 0309459575 |
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Author | : |
Publisher | : |
Total Pages | : 1796 |
Release | : 2006 |
Genre | : Drug interactions |
ISBN | : |
Author | : |
Publisher | : Academic Press |
Total Pages | : 288 |
Release | : 2019-07-13 |
Genre | : Medical |
ISBN | : 0128173173 |
Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. Includes the authority and expertise of leading contributors in pharmacology Presents the latest release in the Advances in Pharmacology series
Author | : Ornella Corazza |
Publisher | : Springer |
Total Pages | : 192 |
Release | : 2017-08-09 |
Genre | : Business & Economics |
ISBN | : 331960600X |
In light of the recent emergence of Novel Psychoactive Substances (NPS) on a global scale, this book provides a timely analysis of the social and economic impact of the NPS phenomenon, and of the global policy and regulatory responses to it. It presents the first comprehensive overview of the international regulation, policy and market structure of the NPS phenomenon, offering a guide to inform legislative discussions and demonstrating from a comparative perspective the different approaches used to address the rise of NPS to date. It covers topics such as organized crime, drug markets, clinical evidence on NPS, and different regulatory approaches also in less explored settings such as prisons and sport environments. Overall, this highly informative and well-structured repository of different experiences with NPS policy, law and regulation offers an essential primary source of evidence for anyone interested in the area of drug and NPS policy, health economics and p ublic health.
Author | : Michael J. Klepper |
Publisher | : Jones & Bartlett Learning |
Total Pages | : 332 |
Release | : 2011 |
Genre | : Medical |
ISBN | : 0763769126 |
Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk provides pharmaceutical scientists, researchers and technicians with an accessible, practical framework for the analysis, summary and interpretation of drug safety data. The only guide of its kind, Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk is an invaluable reference for premarketing risk assessment. This unique resource enhances the ability of pharmaceutical professionalsùthose with and without clinical trainingùto determine the risk of a drug or biologic ahead of its release, thereby reducing unnecessary jeopardy to the patient. Authors Dr. Michael Klepper and Dr. Barton Cobert, who together bring decades of pharmaceutical research and drug safety expertise, discuss how quality planning, safety training and data standardization result in significant cost, time and resource savings. Through illustrative, step-by-step instruction, Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk provides the definitive guide to drug safety data analysis and reporting. Key features include: Step-by-step instruction on how to analyze, summarize and interpret safety data for mandatory governmental safety reports Pragmatic tipsàand mistakes to avoid Simple explanations of what safety data are collected, and what the data mean Practical approaches to determining a drug effect and understanding its clinical significance Guidance for determining risk throughout the lifecycle of a drug, biologic or nutraceutical Examples of user-friendly data displays that enhance safety signal identification Ways to improve data quality and reduce the time, resources and costs involved in mandatory safety reporting Relevant material for the required training of drug safety/pharmacovigilance professionals SPECIAL FEATURE: Actual examples of an Integrated Analysis of Safety (IAS) -used in the preparation of the Integrated Summary of Safety (ISS) and the Summary of Clinical Safety (SCS) reports -, and the Periodic Safety Update Report (PSUR)